Cachexia - Pipeline Review, H2 2015

Date: September 30, 2015
Pages: 158
Price:
US$ 2,000.00 US$ 1,600.00
Offer valid until December 31, 2016!
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: C5084C01EEEEN
Leaflet:

Download PDF Leaflet

Cachexia - Pipeline Review, H2 2015

SUMMARY

Global Markets Direct’s, ‘Cachexia - Pipeline Review, H2 2015’, provides an overview of the Cachexia’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Cachexia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cachexia and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

SCOPE
  • The report provides a snapshot of the global therapeutic landscape of Cachexia
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Cachexia and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Cachexia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Cachexia pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
REASONS TO BUY
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Cachexia
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Cachexia pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Introduction
Global Markets Direct Report Coverage
Cachexia Overview
Therapeutics Development
Pipeline Products for Cachexia - Overview
Pipeline Products for Cachexia - Comparative Analysis
Cachexia - Therapeutics under Development by Companies
Cachexia - Therapeutics under Investigation by Universities/Institutes
Cachexia - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Unknown Stage Products
Cachexia - Products under Development by Companies
Cachexia - Products under Investigation by Universities/Institutes
Cachexia - Companies Involved in Therapeutics Development
Acacia Pharma Limited
Aeterna Zentaris Inc.
Amgen Inc.
Aphios Corporation
Atara Biotherapeutics, Inc.
Connexios Life Sciences Pvt. Ltd.
Eli Lilly and Company
GlaxoSmithKline Plc
GTx, Inc.
Helsinn Healthcare S.A.
Incyte Corporation
KAEL-GemVax Co., Ltd.
MI.TO. Technology S.r.L.
Myos Corporation
Novartis AG
Obexia AG
PolyNovo Limited
PsiOxus Therapeutics Limited
Radius Health, Inc.
RaQualia Pharma Inc.
Rhythm Pharmaceuticals
VBS Pharmaceuticals
Vicus Therapeutics, LLC
Viking Therapeutics, Inc.
Cachexia - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
(etodolac + propranolol hydrochloride) - Drug Profile
(formoterol fumarate + megestrol acetate) - Drug Profile
anamorelin hydrochloride - Drug Profile
Antibody to Inhibit Parathyroid Hormone Related Protein for Cancer Cachexia - Drug Profile
AOD-9604 - Drug Profile
Aptamer to Activate Calcineurin A for Genetic Disorders and Musculoskeletal Disorders - Drug Profile
ARM-210 - Drug Profile
ATA-842 - Drug Profile
AV-380 - Drug Profile
bimagrumab - Drug Profile
C-1889 - Drug Profile
CAR Peptide - Drug Profile
CNX-013B2 - Drug Profile
DLN-101 - Drug Profile
dronabinol - Drug Profile
Drug to Antagonize ActRIIB for Cancer Cachexia - Drug Profile
enobosarm - Drug Profile
Espindolol - Drug Profile
EXT-400 - Drug Profile
GSK-2881078 - Drug Profile
landogrozumab - Drug Profile
macimorelin acetate - Drug Profile
Monoclonal Antibody to Antagonize TWEAK Receptor for Cachexia and Cancer Cachexia - Drug Profile
NBD Peptide - Drug Profile
OBX-1201 - Drug Profile
Proteins for Musculoskeletal Disorders - Drug Profile
RAD-140 - Drug Profile
relamorelin - Drug Profile
RQ-00432933 - Drug Profile
ruxolitinib phosphate - Drug Profile
Small Molecule to Agonize Ghrelin Receptor for Cancer Cachexia and Anorexia - Drug Profile
Small Molecule to Inhibit ATGL for Cancer Cachexia and Type 2 Diabetes - Drug Profile
Small Molecules to Inhibit Furin for Sarcopenia and Cachexia - Drug Profile
Small Molecules to Inhibit JAK3 for Rheumatoid Arthritis, Sarcopenia and Cachexia - Drug Profile
Small Molecules to Inversely Agonize Beta3-Adrenoreceptor for Cachexia, Metabolic Syndrome and Heart Failure - Drug Profile
Small Molecules to Target Melanocortin-4 Receptor for Cachexia - Drug Profile
Synthetic Peptide to Inhibit Melanocortin Receptor for Cancer Cachexia - Drug Profile
Synthetic Peptides for Cancer Cachexia - Drug Profile
tertomotide - Drug Profile
VK-5211 - Drug Profile
Cachexia - Recent Pipeline Updates
Cachexia - Dormant Projects
Cachexia - Discontinued Products
Cachexia - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Cachexia, H2 2015
Number of Products under Development for Cachexia - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Development, H2 2015
Comparative Analysis by Unknown Stage Development, H2 2015
Products under Development by Companies, H2 2015
Products under Development by Companies, H2 2015 (Contd.1)
Products under Development by Companies, H2 2015 (Contd.2)
Products under Investigation by Universities/Institutes, H2 2015
Cachexia - Pipeline by Acacia Pharma Limited, H2 2015
Cachexia - Pipeline by Aeterna Zentaris Inc., H2 2015
Cachexia - Pipeline by Amgen Inc., H2 2015
Cachexia - Pipeline by Aphios Corporation, H2 2015
Cachexia - Pipeline by Atara Biotherapeutics, Inc., H2 2015
Cachexia - Pipeline by Connexios Life Sciences Pvt. Ltd., H2 2015
Cachexia - Pipeline by Eli Lilly and Company, H2 2015
Cachexia - Pipeline by GlaxoSmithKline Plc, H2 2015
Cachexia - Pipeline by GTx, Inc., H2 2015
Cachexia - Pipeline by Helsinn Healthcare S.A., H2 2015
Cachexia - Pipeline by Incyte Corporation, H2 2015
Cachexia - Pipeline by KAEL-GemVax Co., Ltd., H2 2015
Cachexia - Pipeline by MI.TO. Technology S.r.L., H2 2015
Cachexia - Pipeline by Myos Corporation, H2 2015
Cachexia - Pipeline by Novartis AG, H2 2015
Cachexia - Pipeline by Obexia AG, H2 2015
Cachexia - Pipeline by PolyNovo Limited, H2 2015
Cachexia - Pipeline by PsiOxus Therapeutics Limited, H2 2015
Cachexia - Pipeline by Radius Health, Inc., H2 2015
Cachexia - Pipeline by RaQualia Pharma Inc., H2 2015
Cachexia - Pipeline by Rhythm Pharmaceuticals, H2 2015
Cachexia - Pipeline by VBS Pharmaceuticals, H2 2015
Cachexia - Pipeline by Vicus Therapeutics, LLC, H2 2015
Cachexia - Pipeline by Viking Therapeutics, Inc., H2 2015
Assessment by Monotherapy Products, H2 2015
Assessment by Combination Products, H2 2015
Number of Products by Stage and Target, H2 2015
Number of Products by Stage and Mechanism of Action, H2 2015
Number of Products by Stage and Route of Administration, H2 2015
Number of Products by Stage and Molecule Type, H2 2015
Cachexia Therapeutics - Recent Pipeline Updates, H2 2015
Cachexia - Dormant Projects, H2 2015
Cachexia - Dormant Projects (Contd.1), H2 2015
Cachexia - Dormant Projects (Contd.2), H2 2015
Cachexia - Discontinued Products, H2 2015

LIST OF FIGURES

Number of Products under Development for Cachexia, H2 2015
Number of Products under Development for Cachexia - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Products, H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Top 10 Targets, H2 2015
Number of Products by Stage and Top 10 Targets, H2 2015
Number of Products by Top 10 Mechanism of Actions, H2 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
Number of Products by Top 10 Routes of Administration, H2 2015
Number of Products by Stage and Top 10 Routes of Administration, H2 2015
Number of Products by Top 10 Molecule Types, H2 2015
Number of Products by Stage and Top 10 Molecule Types, H2 2015

COMPANIES MENTIONED

Acacia Pharma Limited
Aeterna Zentaris Inc.
Amgen Inc.
Aphios Corporation
Atara Biotherapeutics, Inc.
Connexios Life Sciences Pvt. Ltd.
Eli Lilly and Company
GlaxoSmithKline Plc
GTx, Inc.
Helsinn Healthcare S.A.
Incyte Corporation
KAEL-GemVax Co., Ltd.
MI.TO. Technology S.r.L.
Myos Corporation
Novartis AG
Obexia AG
PolyNovo Limited
PsiOxus Therapeutics Limited
Radius Health, Inc.
RaQualia Pharma Inc.
Rhythm Pharmaceuticals
VBS Pharmaceuticals
Vicus Therapeutics, LLC
Viking Therapeutics, Inc.
Skip to top


Cancer Cachexia - Pipeline Review, H2 2016 US$ 2,000.00 Jul, 2016 · 108 pages

Ask Your Question

Cachexia - Pipeline Review, H2 2015
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: